[1]
ABIOLA, D. et al. 2016. Management of type 1 and type 2 diabetes requiring insulin. Prescriber. (2016).
[2]
ABIOLA, D. et al. 2016. Management of type 1 and type 2 diabetes requiring insulin. Prescriber. (2016).
[3]
Bangstad, H.-J. et al. 2009. Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes. 10, 6 (2009), 82–99. DOI:https://doi.org/10.1111/j.1399-5448.2009.00578.x.
[4]
Caverly, T.J. et al. 2015. Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia. JAMA Internal Medicine. (Oct. 2015). DOI:https://doi.org/10.1001/jamainternmed.2015.5950.
[5]
Chen, L. et al. 2015. Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis. Metabolism. 64, 2 (Feb. 2015), 338–347.
[6]
Complications of Diabetes Mellitus | InTechOpen: https://www.intechopen.com/books/pathophysiology-and-complications-of-diabetes-mellitus.
[7]
Crowley, M.J. et al. 2017. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease. Annals of Internal Medicine. 166, 3 (Feb. 2017). DOI:https://doi.org/10.7326/M16-1901.
[8]
Dauriz, M. et al. 2017. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care. 40, 5 (May 2017), 671–678. DOI:https://doi.org/10.2337/dc16-2016.
[9]
Essential Values-Based Practice is supported by a website jointly hosted by Cambridge University Press and Warwick Medical School at http://www.go.warwick.ac.uk/values-basedpractice: http://valuesbasedpractice.org/.
[10]
Ettehad, D. et al. 2015. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. (Dec. 2015). DOI:https://doi.org/10.1016/S0140-6736(15)01225-8.
[11]
Fadini, G.P. et al. 2017. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 60, 8 (Aug. 2017), 1385–1389.
[12]
Filippatos, T.D. et al. 2016. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy. 17, 12 (2016), 1581–1583.
[13]
Filippatos, T.D. et al. 2016. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opinion on Pharmacotherapy. 17, 12 (2016), 1581–1583.
[14]
Fralick, M. et al. 2017. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine. 376, 23 (Jun. 2017), 2300–2302.
[15]
Gæde, P. et al. 2008. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine. 358, 6 (2008), 580–591.
[16]
Gæde, P. et al. 2016. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 59, 11 (Nov. 2016), 2298–2307. DOI:https://doi.org/10.1007/s00125-016-4065-6.
[17]
Green, J.B. et al. 2015. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 373, 3 (2015), 232–242.
[18]
Hine, J. et al. 2015. SGLT inhibition and euglycaemic diabetic ketoacidosis. The Lancet Diabetes & Endocrinology. 3, 7 (2015), 503–504.
[19]
Inzucchi, S.E. et al. 2015. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research. 12, 2 (2015), 90–100. DOI:https://doi.org/10.1177/1479164114559852.
[20]
Ismail, K. et al. 2004. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. The Lancet. 363, 9421 (May 2004), 1589–1597.
[21]
Kosiborod, M. et al. 2017. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective. Circulation. 136, 3 (Jul. 2017), 249–259.
[22]
Lipska, K.J. et al. 2016. Polypharmacy in the Aging Patient. JAMA. 315, 10 (Mar. 2016). DOI:https://doi.org/10.1001/jama.2016.0299.
[23]
Marso, S.P. et al. 2017. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine. (2017).
[24]
Marso, S.P. et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 375, 19 (2016), 1834–1844. DOI:https://doi.org/10.1056/NEJMoa1607141.
[25]
Marso, S.P. et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 375, 19 (2016), 1834–1844. DOI:https://doi.org/10.1056/NEJMoa1607141.
[26]
Maruthur, N.M. et al. 2016. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Annals of Internal Medicine. 164, 11 (2016). DOI:https://doi.org/10.7326/M15-2650.
[27]
Nauck, M.A. 2013. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks. Diabetes Care. 36, 7 (Jul. 2013), 2126–2132. DOI:https://doi.org/10.2337/dc12-2504.
[28]
Neal, B. et al. 2017. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 377 (2017), 644–657.
[29]
NHS Evidence, an offshoot of NICE, provides basic information on evidence-based management of many common conditions, including diabetes, and can be found at https://www.evidence.nhs.uk/: https://www.evidence.nhs.uk/.
[30]
Paul, S.K. et al. 2015. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology. 14, 1 (Dec. 2015). DOI:https://doi.org/10.1186/s12933-015-0260-x.
[31]
Pfeffer, M.A. et al. 2015. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 373, 23 (2015), 2247–2257.
[32]
Pieber, T.R. et al. 2018. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 61, 1 (Jan. 2018), 58–65.
[33]
Rang, H. 2012. Pharmacokinetics. Rang & Dale’s pharmacology. Elsevier/Churchill Livingstone. 123–131.
[34]
Scheen, A.J. 2016. SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports. 16, 10 (Oct. 2016). DOI:https://doi.org/10.1007/s11892-016-0789-4.
[35]
Scirica, B.M. et al. 2013. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 369, 14 (Oct. 2013), 1317–1326. DOI:https://doi.org/10.1056/NEJMoa1307684.
[36]
Scirica, B.M. et al. 2013. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 369, 14 (Oct. 2013), 1317–1326.
[37]
Sinclair, A.J. et al. 2016. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society. 64, 3 (2016), 543–552. DOI:https://doi.org/10.1111/jgs.14028.
[38]
The Action to Control Cardiovascular Risk in Diabetes Study Group 2008. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 358, 24 (Jun. 2008), 2545–2559.
[39]
The ADVANCE Collaborative Group 2008. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 358, 24 (Jun. 2008), 2560–2572.
[40]
The American Diabetes Association: https://www.diabetes.org/.
[41]
The Cochrane collaboration at http://www.cochrane.org/ helps "healthcare practitioners, policy-makers, patients, their advocates and carers make well-informed decisions about health care, by preparing, updating, and promoting the accessibility of Cochrane Reviews.”: http://www.cochrane.org/.
[42]
The commercial but not-for-profit Trip database at http://www.tripdatabase.com claims to be "the internet’s premier source of evidence-based content”: http://www.tripdatabase.com/.
[43]
The Critical Appraisal Skills Programme (CASP) critical appraisal checklists can be downloaded from http://www.casp-uk.net/: https://casp-uk.net/casp-tools-checklists/.
[44]
The European Association for the Study of Diabetes (EASD): http://www.easd.org/.
[45]
The George Eliot Diabetes Care Team’s Alphabet Strategy website is at www.abcdiabetes.co.uk: http://www.abcdiabetes.co.uk/.
[46]
The International Diabetes Federation (IDF) is at http://www.idf.org: http://www.idf.org/.
[47]
The Scottish Intercollegiate Guidelines Network website is at http://www.sign.ac.uk: http://www.sign.ac.uk/.
[48]
Vaccaro, O. et al. 2017. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. The Lancet Diabetes & Endocrinology. 5, 11 (Nov. 2017), 887–897. DOI:https://doi.org/10.1016/S2213-8587(17)30317-0.
[49]
Wanner, C. et al. 2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 323–334. DOI:https://doi.org/10.1056/NEJMoa1515920.
[50]
Wu, J.H.Y. et al. 2016. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 4, 5 (May 2016), 411–419. DOI:https://doi.org/10.1016/S2213-8587(16)00052-8.
[51]
Young, L.A. et al. 2017. Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings. JAMA Internal Medicine. 177, 7 (Jul. 2017). DOI:https://doi.org/10.1001/jamainternmed.2017.1233.
[52]
Zeitler, P. et al. 2014. Type 2 diabetes in child and adolescent. Pediatric Diabetes. 15, (2014), 26–46.
[53]
Zinman, B. et al. 2015. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 373, 22 (Nov. 2015), 2117–2128. DOI:https://doi.org/10.1056/NEJMoa1504720.
[54]
Zinman, B. et al. 2015. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 373, 22 (2015), 2117–2128. DOI:https://doi.org/10.1056/NEJMoa1504720.
[55]
Zinman, B. et al. 2015. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 373, 22 (Nov. 2015), 2117–2128. DOI:https://doi.org/10.1056/NEJMoa1504720.
[56]
2017. Diabetes Care: 40 (Supplement 1). Diabetes Care. 40, Supplement 1 (2017).
[57]
2008. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 358, 24 (Jun. 2008), 2545–2559. DOI:https://doi.org/10.1056/NEJMoa0802743.
[58]
2015. Effects of Liraglutide on Glycemic Control :Cleveland Clinic Journal of Medicine. (2015).
[59]
Pediatric Diabetes. 15, S20.